Develops a non-invasive biopsy platform that analyzes extracellular vesicles (EVs) in blood samples to provide organ-specific insights into disease processes. This technology improves early liver cancer detection in high-risk patients by combining the accuracy of tissue biopsies with the convenience of liquid biopsy, achieving 86% sensitivity and 88% specificity for early-stage cancer.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current liver cancer surveillance methods, such as ultrasound, lack sufficient sensitivity, especially in high-risk individuals with conditions like cirrhosis, leading to low detection rates and poor patient adherence. These methods struggle to detect small tumors, particularly in overweight patients, and require separate appointments from routine blood tests.
Solution
Mursla Bio offers a non-invasive "Dynamic Biopsy" platform that analyzes organ-specific extracellular vesicles (EVs) in blood samples, providing a more accurate and convenient method for early liver cancer detection. This liquid biopsy approach combines the accuracy of tissue biopsies with the simplicity of blood sample collection. By isolating hepatocyte-specific EVs and applying an AI-enabled multi-omics biomarker discovery workflow, Mursla Bio's EvoLiver test achieves significantly improved sensitivity and specificity compared to existing surveillance techniques. The platform enables the identification of novel HCC biomarker signatures, distinguishing cancerous cirrhosis from non-cancerous cirrhosis, and supports improved patient outcomes through early detection and streamlined disease management.
Target Audience
The primary target audience includes individuals at high risk of developing liver cancer, particularly those with cirrhosis, as well as healthcare providers and clinical researchers focused on improving early cancer detection and patient outcomes.
Features
- Non-invasive liquid biopsy approach using extracellular vesicles (EVs)
- Organ-specific EV isolation from biofluids for precise targeting of the liver
- AI-enabled multi-omics biomarker discovery workflow for identifying disease biomarkers
- Scalable assay platform using optimal biomarkers for clinical use
- EvoLiver test demonstrates 86% early-stage sensitivity and 88% specificity for liver cancer surveillance in high-risk patients
- Low blood volume requirement and quick turnaround times
- Potential to replace ultrasound in liver cancer surveillance
- FDA Breakthrough Device Designation for EvoLiver™